

Nuclea Biotechnologies partners with BacterioScan, 4/15

April 2015—Nuclea Biotechnologies is partnering with St. Louis-based BacterioScan to validate the BacterioScan 216Dx instrument in a CLIA-certified laboratory. This collaboration will focus on antimicrobial susceptibility testing to guide the best course of antibiotic treatment for different strains of urinary tract infections.

BacterioScan is an in vitro diagnostics company that focuses on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. The company offers microbial lab technology that enables researchers to quantify bacterial concentration and growth in a liquid in less than 20 minutes.

The BacterioScan 216Dx instrument is a laser microbial growth monitor used to detect and quantify bacterial concentrations that would typically fall below the detection limits of spectrophotometers and plate reader optical density measurements, potentially enabling more rapid selection of the right antibiotic treatment at the right dose. Initial work, including recent publications from the Centers for Disease Control and Prevention and others, has indicated that the technology can reduce the time for selection of effective antibiotic therapy from 30-plus hours to less than three hours, offering a potential breakthrough in addressing the challenge of antibiotic resistance.

The BacterioScan instrument will be integrated within Nuclea's CLIA laboratory in Pittsfield, Mass., by the first half of 2015.

[Nuclea Biotechnologies](#), 413-749-4705